Article

Laser has CE mark approval

Upon receiving CE mark approval to market in Europe, OptiMedica Corp. expects to begin shipping its laser system for cataract surgery (Catalys Precision) in the fourth quarter of this year.

Santa Clara, CA-Upon receiving CE mark approval for marketing in Europe, OptiMedica Corp. expects to begin shipping its laser system for cataract surgery (Catalys Precision) in the fourth quarter of this year.

The system is CE mark-approved to deliver capsulotomy and lens fragmentation. The company expects the system to receive CE mark approval for corneal incisions soon.

It combines a femtosecond laser, integrated optical coherence tomography imaging, and the company’s pattern scanning technology. The system is designed to be ergonomic and easy to use to improve the precision and accuracy of cataract surgery.

Key innovations, according to the company, include an interface designed to ensure stable system-patient attachment and to optimize the optical path to the patient’s eye, a proprietary guidance system designed to ensure that the femtosecond laser pulses are delivered safely and precisely to the intended location, and a graphical user interface created to simplify the planning process and to minimize the time that the patient is under the dock.

“We believe that the field of cataract surgery is in the midst of a revolutionary change, and we expect [the system] to provide leading technology that satisfies the high expectations of surgeons and their patients,” said Mark J. Forchette, OptiMedica president and chief executive officer. The company expects to introduce the system to markets around the world soon, he added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.